Program
Losartan
Also written as “losartan potassium”, “Amlodipine plus Losartan” and “Losartan (COZZAR®)”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetes Mellitus, Type 2 · Proteinuria · Heart Failure, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 120 open or running | phase 4since Aug 30, 2005 | Aug 25, 2004 | none ahead |
| Hanmi Pharmaceutical | 80 open or running | phase 3since Jul 14, 2009 | Jul 14, 2009 | none ahead |
| Merck | 60 open or running | phase 3since Apr 14, 2009 | Feb 27, 2009 | none ahead |
| Torrent Pharmaceuticals | 40 open or running | phase 1since Oct 7, 2010 | Oct 7, 2010 | none ahead |
| Hikma Pharmaceuticals | 30 open or running | no phasesince Apr 9, 2010 | Apr 9, 2010 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 20 open or running | phase 3since Jun 8, 2021 | Jun 8, 2021 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since May 13, 2010 | May 13, 2010 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| invasc-therapeutics-inc | 10 open or running | phase 4since Jan 5, 2011 | Jan 5, 2011 | none ahead |
| Medtronic | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Feb 27, 2018 | Feb 27, 2018 | none ahead |
Also a collaborator on its studies: reliance-life-sciences-private-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Aug 25, 2004.
- May 13, 2010Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT01124175, NCT01124162
- May 19, 2010Phase 3 study in HypertensionHanmi Pharmaceutical · NCT01127217 · 149 enrolled · Korea, Republic of
- Sep 7, 20102 phase 1 studies in HealthyHanmi Pharmaceutical · NCT01197014, NCT01197001
- Oct 6, 20102 no phase studies in HypertensionHikma Pharmaceuticals · NCT01216878, NCT01216852
- Oct 7, 2010Torrent Pharmaceuticals's first studies: 4 phase 1 studies in HealthyNew to Torrent PharmaceuticalsTorrent Pharmaceuticals · NCT01218724, NCT01218711, NCT01218698 and 1 more
- Jan 5, 2011invasc-therapeutics-inc's first study: phase 4 study in HypertensionNew to invasc-therapeutics-incinvasc-therapeutics-inc · NCT01271374 · 80 enrolled · United States
- Feb 22, 2011Phase 3 study in HypertensionMerck · NCT01302691 · 327 enrolled
- Sep 7, 2011Phase 4 study in HypertensionOrganon · NCT01431508 · 15 enrolled
- Sep 21, 2012Azidus Brasil's first study: phase 1 study in Healthy SubjectsNew to Azidus BrasilAzidus Brasil · NCT01692717 · 90 enrolled · Brazil
- Dec 17, 2014Phase 1 study in HypertensionHanmi Pharmaceutical · NCT02387554 · 33 enrolled · Korea, Republic of
- Feb 23, 2016Phase 1 study in HealthyHanmi Pharmaceutical · NCT04252872 · 64 enrolled · Korea, Republic of
- Feb 27, 2018Pharmtechnology's first study: phase 1 study in HealthyNew to PharmtechnologyPharmtechnology · NCT03459911 · 66 enrolled · India
- Jun 8, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in HypertensionNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04927299 · 163 enrolled · Mexico
- Oct 8, 2021Phase 1 study in HealthyLaboratorios Silanes S.A. de C.V. · NCT05090449 · 36 enrolled · Mexico
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Telmisartanrule | Boehringer Ingelheim | phase 4 | 132 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
All 41 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05090449Healthy · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Apr 8, 2020 | 36 |
| NCT04927299Hypertension · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Aug 15, 2023 | 163 |
| NCT03459911Healthy · India | 1 | Completed | Pharmtechnology | Mar 11, 2018 | 66 |
| NCT04252872Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Nov 2015 | 64 |
| NCT02387554Hypertension · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Oct 2014 | 33 |
| NCT01692717Healthy Subjects · Brazil | 1 | Completed | Azidus Brasil | May 31, 2013 | 90 |
| NCT01431508Hypertension | 4 | Completed | Organon | Jun 1, 2009 | 15 |
| NCT01302691Hypertension | 3 | Completed | Merck | Apr 1, 2012 | 327 |
| NCT01271374Hypertension · United States | 4 | UNKNOWN | invasc-therapeutics-inc | Jun 2011 | 80 |
| NCT01218724Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT01218711Healthy | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT01218698Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT01218022Healthy · India | 1 | Completed | Torrent Pharmaceuticals | ||
| NCT01216878Hypertension · United States | – | Completed | Hikma Pharmaceuticals | Sep 2004 | 40 |
| NCT01216852Hypertension · United States | – | Completed | Hikma Pharmaceuticals | Aug 2004 | 40 |
| NCT01197014Healthy · Czech Republic | 1 | Completed | Hanmi Pharmaceutical | Nov 2010 | 72 |
| NCT01197001Healthy · Czech Republic | 1 | Completed | Hanmi Pharmaceutical | Oct 2010 | 72 |
| NCT01127217Hypertension · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Mar 2010 | 149 |
| NCT01124175Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2003 | 80 |
| NCT01124162Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2003 | 80 |
| NCT01102478Hypertension · United States | – | Completed | Hikma Pharmaceuticals | Mar 2005 | 30 |
| NCT00953680Hypertension | 1 | Completed | Organon | May 2004 | 77 |
| NCT00943852Hypertension | 1 | Completed | Organon | Dec 2006 | 13 |
| NCT00942344Hypertension · Korea, Republic of | 2 | Completed | Hanmi Pharmaceutical | Dec 2007 | 320 |
| NCT00940680Hypertension · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Nov 2008 | 142 |
| NCT00940667Hypertension · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Dec 2008 | 185 |
| NCT00888355Hypertension | 3 | Completed | Merck | Jan 1993 | 428 |
| NCT00887250Hypertension | 3 | Completed | Merck | Aug 1992 | 366 |
| NCT00886600Hypertension | 3 | Completed | Merck | May 1992 | 122 |
| NCT00882440Hypertension | 3 | Completed | Merck | Aug 1991 | 576 |
| NCT00856960Hypertension | 1 | Completed | Merck | Mar 2010 | 12 |
| NCT00756938Hypertension | 3 | Completed | Organon | Aug 14, 2012 | 101 |
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Medtronic | Jul 2007 | 164 |
| NCT00568178Proteinuria | 3 | Completed | Organon | Sep 1, 2008 | 306 |
| NCT00496834Hypertension | 4 | Completed | Organon | Sep 1, 2009 | 201 |
| NCT00449111Hypertension | 3 | Terminated | Organon | Sep 30, 2006 | 11 |
| NCT00308347Diabetes Mellitus, Type 2 | 3 | Completed | Organon | Feb 2001 | 1,513 |
| NCT00307060Mild to Severe Hypertension | 3 | Completed | Organon | Jun 1, 2005 | 274 |
| NCT00289887Hypertension | 3 | Completed | Organon | Feb 2007 | 261 |
| NCT00140907Hypertension | 4 | Completed | Organon | Jan 1, 2005 | 367 |
| NCT00090259Heart Failure | 3 | Completed | Organon | Mar 31, 2009 | 3,834 |
How it is read
Names in the registry
- “losartan potassium”, 10 entries
- “Losartan”, 8 entries
- “Amlodipine plus Losartan”, 5 entries
- “Losartan (COZZAR®)”, 2 entries
- “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
Codes read as this program: MK0954.
Conditions, from the studies’ own filings
- Hypertension, 34 studies
- Essential Hypertension, 5 studies
- Diabetes Mellitus, Type 2, 2 studies
- Proteinuria, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.